FIGURE 1


Screening/Baseline
Characterization
Period 1:
Randomized Double
Blinded Placebo
Controlled
Period 2:
Open Label REGN2477
Treatment
Period 3:
Follow-Up REGN2477
Treatment
Screening
followed by 1:1
Randomization
REGN2477
Placebo IV
REGN2477
REGN2477
Treatment
Follow-Up
Baseline
D1 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 W56 W76 W80
18F-NaF PET
Low Dose CT